LumiThera Shows Improved AMD Trial Results - Data Intelligence

LumiThera’s LIGHTSITE Phase 3B Extension Trial Shows Extended Vision Improvement in Dry AMD

LumiThera announced the topline results from the LIGHTSITE 3B extension trial, a prospective, open-label trial in dry age-related macular degeneration (AMD) subjects. The extension trial followed subjects that completed the pivotal LIGHTSITE 3 trial and resumed treatment for 13 months with the Valeda Light Delivery System.  Approved in November 2024, Valeda is the first FDA-authorized treatment to improve vision in dry AMD patients. In the LIGHT…

LumiThera shows improved AMD trial results

LumiThera has released new topline data for its Valeda Light Delivery System to slow the progression of dry age-related macular degeneration.The post LumiThera shows improved AMD trial results appeared first on Medical Device Network.

LumiThera Shows Improved AMD Trial Results - Data Intelligence

The extension trial has extended out the efficacy of LumiThera’s therapy from 24 months to 4.5 years. Image credit: Leonardo Gabriel Tallone via Shutterstock. LumiThera has released new topline data for its Valeda Light Delivery System treatment for slowing the progression of dry age-related macular degeneration (AMD). LumiThera’s Valeda became the first non-invasive approach for treating dry AMD following its authorisation by the US Food and Dr…